Associated tags: Engineering, HER2, Drug development, Conjugation, Zymeworks, Patient, Pharmaceutical industry, Biotechnology, Research, Health, Inc., Pharmaceutical
Locations: NEW YORK, CALIFORNIA, SAN FRANCISCO, ASIA, APAC, SINGAPORE, NY, FL, NV, MA, BENCHMARK, CHINA, ITALY, TD, CA, LOS ANGELES, TEL AVIV, PARIS, MIDDLETOWN, DE, US, BRITISH COLUMBIA, NORTH AMERICA, EUROPE, UNITED STATES, CHICAGO, LONDON
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
Key Points:
- NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
- 7980
The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
- The Firm has recovered billions of dollars in damages awards on behalf of class members.
Transfer,
Breast cancer,
FDA,
The Transfer Agreement,
Food,
BTC,
Research,
Trastuzumab,
MAA,
Insurance,
Jazz Pharmaceuticals,
MSAT,
Abstract,
IND,
ASCO,
Disease,
CD28,
HER2,
Tax,
ADC,
Three Months,
Patient,
Society,
EMA,
Bone marrow,
BLA,
Standard of care,
AACR,
Autoimmunity,
European Medicines Agency,
Pharmaceutical industry In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
Key Points:
- In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
- Financial Results for the Three Months Ended March 31, 2024
Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.
- Other income, net increased by $1.9 million for the three months ended March 31, 2024 compared to the same period in 2023.
- Net loss for the three months ended March 31, 2024 was $31.7 million compared to $24.4 million loss for the same period in 2023.
Retrieved on:
Wednesday, April 24, 2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
Key Points:
- NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
- 7980
The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
- The Firm has recovered billions of dollars in damages awards on behalf of class members.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
Key Points:
- NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
- 7980
The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
- The Firm has recovered billions of dollars in damages awards on behalf of class members.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.
Key Points:
- VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.
- Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET).
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
Key Points:
- NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
- 7980
The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
- The Firm has recovered billions of dollars in damages awards on behalf of class members.
Well,
Small-cell carcinoma,
Therapeutic index,
Glomus tumor,
Endometrial cancer,
Survival,
Environment,
Service provider,
Trichloroethylene,
Patient,
Primate,
Triple-negative breast cancer,
Lead,
Zymeworks,
3D,
Standard of care,
Cancer,
TAA,
Spacecraft,
Lung cancer,
IND,
CD3,
DLL3,
AACR,
Workflow,
Antibody,
TCE,
CD28,
Therapy,
Stomach,
ADC,
Vaccine The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
Key Points:
- The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
- An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
- Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME) on behalf of Zymeworks stockholders.
Key Points:
- NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME) on behalf of Zymeworks stockholders.
- Our investigation concerns whether Zymeworks has violated the federal securities laws and/or engaged in other unlawful business practices.
- On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle (“Astle”) from the positions of Senior Vice President (“SVP”) and Chief Financial Officer (“CFO”), effective immediately.
- On this news, Zymeworks’s stock price fell $0.64 per share, or 6.08%, to close at $9.88 per share on April 1, 2024.
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).
Key Points:
- NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ).
- The investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
- On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, effective immediately.
- Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
Key Points:
- NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
- 7980
The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
- The Firm has recovered billions of dollars in damages awards on behalf of class members.
